Prelude Therapeutics (PRLD) Revenue & Revenue Breakdown
Prelude Therapeutics Revenue Highlights
Prelude Therapeutics Revenue by Period
Prelude Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Prelude Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Prelude Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $3.42M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Prelude Therapeutics generated - in revenue during Q1 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Prelude Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| BCEL | Atreca | $770.00K | $80.00K |
| RZLT | Rezolute | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| CYT | Cyteir Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| ELYM | Eliem Therapeutics | - | - |
| PRLD | Prelude Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| PEPG | PepGen | - | - |
PRLD Revenue FAQ
What is Prelude Therapeutics’s yearly revenue?
Prelude Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. PRLD's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Prelude Therapeutics’s quarterly revenue?
Prelude Therapeutics's quarterly revenue for Q1 2024 was $0, a 100.00% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $0, a -100.00% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). PRLD's quarterly revenue for Q3 2023 was $3.42M, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Prelude Therapeutics’s revenue growth rate?
Prelude Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.